Latest Safety News

EQ Resources has completed a sharp financial turnaround, moving from solvency concerns to a A$7.1 million FY2026 profit and A$28.2 million of cash. The recovery comes with lower annual production, serious safety shortcomings and substantial dilution, leaving execution as the test for its A$39 million Mt Carbine expansion.

Metallium has moved Flash Joule Heating from tiny laboratory tests to multi-reactor campaigns in Texas, backed by feedstock contracts, offtake and A$125 million raised during FY2026. Yet the ASX-listed group remains pre-revenue, lost A$42.8 million and says continued access to funding is a material uncertainty.

Cauldron Energy has expanded its defined Yanrey uranium resource to 55.6 million pounds of U3O8 after a successful exploration year, while warning that further funding will be needed to continue operations. The project remains dependent on a change to Western Australia’s uranium mining policy.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

Spacetalk Limited (ASX:SPA) has posted a sharply deeper FY26 loss and negative net assets, while its auditor flagged a material uncertainty over the company’s ability to continue as a going concern. The company says a $10 million post-year-end placement, note conversions and new telco agreements give its software-led strategy room to execute.

Zimplats delivered a sharp FY2026 earnings rebound, with revenue up 57% and profit after tax rising to US$276.7 million. The result was driven mainly by stronger PGM prices, while lower sales volumes, higher unit costs, no dividend and rising sulphur dioxide emissions temper the celebration.

Kelsian Group delivered record FY26 earnings and lifted its fully franked dividend, while preparing to become a more focused bus, coach and ferry operator. The next test is execution: completing the conditional tourism sale, mobilising new contracts and delivering against FY27 EBITDA guidance.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.

Saferoads Holdings Limited (ASX:SRH) returned to profit in FY2026 after product sales more than doubled, helped by $5.18 million of purchases from On-Site Rental Group. The result marks progress after the Road Safety Rentals disposal, but the next test is whether growth can continue without a repeat commitment from its largest customer.